Travere Therapeutics Inc to Discuss the Regulatory Update Call Transcript
Good day, and welcome to the Travere Therapeutics Corporate Update Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Chief Financial Officer, Chris Cline. Please go ahead, sir. Thank you.
Great. Thank you, Cynthia. Good afternoon, and thank you all for joining us on short notice today. We'll be covering a regulatory update for sparsentan in IgA nephropathy. A copy of the press release announcing the update is available on our website.
Today's call will be led by our Chief Executive Officer, Dr. Eric Dube; and our Chief Medical Officer, Dr. Jula Inrig; our Senior Vice President of Research and Development, Dr. Bill Rote, will also join us for the Q&A session.
Before we begin, I would like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements within the safe harbor provisions of the Private Securities
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |